Eli Lilly Expands Into Vaccine Market with $3.8 Billion Acquisition Strategy
Eli Lilly and Company announced on May 26 a strategic expansion into the infectious disease sector, confirming agreements to acquire three vaccine-focused biotech firms for a total valuation of up to $3.83 billion. The Indianapolis-based pharmaceutical giant will absorb Washington-based Curevo, Swiss-based LimmaTech Biologics, and a Maryland-based vaccine developer through a structure of upfront cash…